The study investigates the prevalence and duration of taste and smell changes in testicular cancer patients undergoing cisplatin-based chemotherapy. Given the high incidence of these sensory changes (46%-77% for taste and 35%-75% for smell), there is a significant market opportunity for nutritional interventions and supportive care products aimed at improving quality of life and dietary intake in this patient population. The findings may inform the development of targeted oral nutrition supplements (ONS) and dietary management strategies, potentially leading to partnerships with companies specializing in oncology nutrition. Additionally, the study's focus on the long-term consequences of these changes may attract interest from stakeholders in the survivorship care sector, particularly as obesity and metabolic syndrome are prevalent among cancer survivors.